AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Article Link
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review

Progress and analysis in Category 1 new Chinese medicines approved in China

Shufei Yu, Pei Yu, Wenjun Xu, Jun Luo, Lingyi Kong( )
State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Bioactive Natural Product Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 211198, China
Show Author Information

Abstract

China’s 2020 drug registration reform revised the classification of Chinese medicines, while subsequent regulatory provisions further clarified the roles of traditional Chinese medicine (TCM) theory, human use experience, and clinical trial evidence. This review examines approval and development trends of new Chinese medicines since 2015, with a focus on Category 1 innovative Chinese medicines approved between 2020 and August 2026. Using published studies and publicly available regulatory data, we compare registration categories and assess product-level evidence concerning medicinal origins, chemical composition, in vivo disposition, pharmacological mechanisms, and clinical outcomes. Approval records and regulatory submissions increased during the post-2020 observation period, although much of the recent growth in approvals came from Category 3 preparations derived from ancient classical prescriptions. Among 34 products that could be broadly assigned to Category 1 under the current classification, 29 were assigned to the Category 1.1 analytical group and five were Category 1.2 products. Category 1.1 products often arose from clinically used herbal formulas, whereas Category 1.2 products more commonly originated from defined extracts or substances and followed pharmacology-oriented development pathways. Across products, the evidence linking constituents, exposure, mechanisms, and clinical benefit varied considerably. Key challenges include identifying therapeutically relevant constituents in complex preparations, establishing causal mechanisms, and generating evidence beyond marketing approval. Future research should clarify clinical positioning, investigate product-specific direct and indirect routes of action, and incorporate real-world evidence and post-marketing safety surveillance.

References

【1】
【1】
 
 
Chinese Journal of Natural Medicines
Pages 1412-1430

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Yu S, Yu P, Xu W, et al. Progress and analysis in Category 1 new Chinese medicines approved in China. Chinese Journal of Natural Medicines, 2026, 24(12): 1412-1430. https://doi.org/10.1016/S1875-5364(26)61230-7

3

Views

0

Crossref

0

Web of Science

0

Scopus

0

CSCD

Received: 08 October 2026
Revised: 30 October 2026
Accepted: 06 November 2026
Published: 20 December 2026
© 2026, China Pharmaceutical University.